News Headlines

  1. Quantum BioPharma Signs Agreement To Manufacture Oral Drug Formulation Of Its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) For Use In Its Upcoming Phase 2 Multiple Sclerosis Trial 8/11/2025

    Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral drug formulation of Lucid-MS.

  2. Sartorius Stedim Biotech And Nanotein Technologies Partner To Advance Cell Therapy Manufacturing 8/11/2025

    Sartorius Stedim Biotech, a leading partner to the biopharmaceutical industry, and Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a partnership. As part of the collaboration, Sartorius Stedim Biotech will invest up to 3 million US dollars in a minority shareholding in Nanotein Technologies to support the commercialization and joint development of solutions based on its NanoSpark platform.

  3. ProBio Launches GMP AAV Manufacturing Services At Hopewell Facility To Advance Gene Therapy Development And Manufacturing 8/11/2025

    ProBio, a leading contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, today announced the launch of its cGMP Adeno-Associated Virus (AAV) manufacturing services at its 128,000 sq. ft. state-of-the-art facility in Hopewell, New Jersey.

  4. Cosmo And Takeda Renew Strategic Manufacturing Agreement For Global Supply Of Oral Treatment For Ulcerative Colitis 8/8/2025

    Cosmo Pharmaceuticals N.V., a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of its multi-year manufacturing and supply agreement with Takeda, to produce Mesalazine MMX 1200 mg (marketed as Lialda in the USA and as Mezavant in Europe) oral, once-daily treatment for ulcerative colitis, reinforcing its position as a trusted partner for global production of key medicines.

  5. Fujifilm And HORIBA Co-Developed Gene Delivery System To Enhance Productivity In Gene Therapy Manufacturing 8/7/2025

    FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) and HORIBA, Ltd. (President: Masayuki Adachi) today announced the co-development of a novel gene delivery system that significantly enhances productivity in the manufacture of gene therapy products.

  6. Excellos, Lonza, And Akadeum Life Sciences Unite To Advance Cell Therapy Manufacturing Through Enhanced Starting Material Quality 8/6/2025

    Excellos, Lonza, and Akadeum Life Sciences today announce a new project aimed at redefining standards for cell therapy manufacturing by elevating the role of starting material quality.

  7. Intas Pharmaceuticals And Accord Biopharma Become One Of The Largest Global Suppliers Of Pegfilgrastim With Acquisition Of UDENYCA® 8/6/2025

    Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the world's leading suppliers of pegfilgrastim following the successful acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences, Inc.

  8. WACKER And Gearbox Biosciences Announce Strategic Collaboration To Advance Plasmid DNA Manufacturing Technologies 8/6/2025

    High-quality pDNA serves as a foundational source of genetic information in the development of life-saving therapies, yet current manufacturing processes face challenges in terms of scalability, efficiency, and cost-effectiveness.

  9. Sumitomo Chemical Announces An Expansion Of The Production Capacity Of Its Regenerative Medicine And Cell Therapy CDMO Subsidiary 8/5/2025

    Sumitomo Chemical Co., Ltd. (“Sumitomo Chemical” or “the Company”) hereby announces that S-RACMO Co., Ltd. (“S-RACMO”), a subsidiary 66.6% owned by Sumitomo Chemical and 33.4% by Sumitomo Pharma, has completed construction of its third regenerative medicine and cell therapy manufacturing facility, known as CRAFT (*1) (“the Facility”). 

  10. CHO Plus Enters Into Project Agreement With BARDA's BioMaP Consortium To Develop High Productivity Cell Lines For Filovirus Monoclonal Antibody Production 8/5/2025

    Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) for up to $10.4M for developing high productivity Chinese hamster ovary cell lines for manufacturing filovirus monoclonal antibodies for therapeutic use over a 30-month period. The agreement has a base period and two option periods.